These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 9779989)

  • 1. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
    Lebowitz PF; Prendergast GC
    Oncogene; 1998 Sep; 17(11 Reviews):1439-45. PubMed ID: 9779989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
    Feldkamp MM; Lau N; Guha A
    Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
    Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB.
    Du W; Lebowitz PF; Prendergast GC
    Mol Cell Biol; 1999 Mar; 19(3):1831-40. PubMed ID: 10022870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects.
    Prendergast GC; Oliff A
    Semin Cancer Biol; 2000 Dec; 10(6):443-52. PubMed ID: 11170866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.
    Carboni JM; Yan N; Cox AD; Bustelo X; Graham SM; Lynch MJ; Weinmann R; Seizinger BR; Der CJ; Barbacid M
    Oncogene; 1995 May; 10(10):1905-13. PubMed ID: 7761092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors.
    Du W; Prendergast GC
    Cancer Res; 1999 Nov; 59(21):5492-6. PubMed ID: 10554025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression.
    Zhang B; Prendergast GC; Fenton RG
    Cancer Res; 2002 Jan; 62(2):450-8. PubMed ID: 11809695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesyltransferase inhibitors as anticancer agents: current status.
    Zhu K; Hamilton AD; Sebti SM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.
    Graaf MR; Richel DJ; van Noorden CJ; Guchelaar HJ
    Cancer Treat Rev; 2004 Nov; 30(7):609-41. PubMed ID: 15531395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors.
    Prendergast GC; Davide JP; Lebowitz PF; Wechsler-Reya R; Kohl NE
    Cancer Res; 1996 Jun; 56(11):2626-32. PubMed ID: 8653708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Farnesyl transferase inhibitors: one target may be found in another].
    Mazières J; Pradines A; Favre G
    Med Sci (Paris); 2003 Feb; 19(2):211-6. PubMed ID: 12836615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives on farnesyl transferase inhibitors in cancer therapy.
    Mazieres J; Pradines A; Favre G
    Cancer Lett; 2004 Apr; 206(2):159-67. PubMed ID: 15013521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors.
    Pan J; Yeung SC
    Cancer Res; 2005 Oct; 65(20):9109-12. PubMed ID: 16230362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesyltransferase inhibitors define a role for RhoB in controlling neoplastic pathophysiology.
    Prendergast GC
    Histol Histopathol; 2001 Jan; 16(1):269-75. PubMed ID: 11193202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevation of alpha2(I) collagen, a suppressor of Ras transformation, is required for stable phenotypic reversion by farnesyltransferase inhibitors.
    Du W; Lebowitz PF; Prendergast GC
    Cancer Res; 1999 May; 59(9):2059-63. PubMed ID: 10232587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
    Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
    Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.